DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapidcardiologyvalvular diseaseright heartadult congenital heart disease

Tricuspid and pulmonary valve disease

Essential points for quick revision.

!
Escalate

Hypotension, syncope, cyanosis or rapidly worsening venous congestion with severe tricuspid or pulmonary valve disease requires same-day specialist assessment; shock needs emergency echocardiography and critical-care/valve-team escalation.

Synopsis

Recognise right-sided valve disease, define RV consequences and refer before irreversible right-heart failure.

  • Most tricuspid regurgitation (TR) is secondary to annular dilatation from left-heart disease, pulmonary hypertension, atrial fibrillation or RV remodelling; exclude device-lead injury and endocarditis.
  • Severe TR causes giant v waves, a pulsatile liver, ascites, oedema and a pansystolic murmur that increases on inspiration; a quiet murmur does not exclude advanced disease.
  • Pulmonary stenosis is usually congenital; pulmonary regurgitation commonly follows repaired tetralogy of Fallot or prior valvotomy/conduit surgery.

Key red flags

Pulmonary stenosis phenotype

Ejection click, harsh upper-left-sternal systolic murmur, RV heave and exertional dyspnoea/syncope suggest significant RV outflow obstruction.

Investigation priorities

01
12-lead ECG and rhythm monitoringFirst step

Detect AF, atrial enlargement, RV hypertrophy and ventricular arrhythmia.

Management branches

TRSevere tricuspid regurgitation

Severe TR with symptoms, RV enlargement/dysfunction, end-organ congestion or planned left-sided surgery.

  1. Confirm primary versus secondary mechanism and optimise AF, left-sided valve disease, pulmonary pressure and congestion.
  2. If mitral surgery is planned and TR is moderate or severe, discuss concomitant tricuspid repair with the Heart Team.

Key medicines

FurosemideUsually 20-40 mg by mouth once daily initially; titrate to congestion and renal response, with IV treatment for acute decompensation.
Open full textbook Answer 2 questionsCardiology check
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom